Industry News
Cisplatin-Resistant Cancer Cells Sensitive To Experimental Anticancer Drugs Called PARP Inhibitors
Apr 03, 2013
Cisplatin-resistant non-small cell lung cancer cells expressed high levels of hyperactivated PARP1. Cells succumbed to PARP inhibitors in vitro. PARP inhibitor slowed cisplatin-resistant tumor growth in mice... Read More
Studying The Epigenetics Of Hormone Therapy Resistance Leads To New Drug Target
Apr 03, 2013
A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant... Read More
New Study Adds Prostate To Cancers Associated With Lynch Syndrome
Apr 02, 2013
Men with an inherited genetic condition called Lynch syndrome face a higher lifetime risk of developing prostate cancer and appear to develop the disease at an earlier age, according to a new study led by researchers at the University of Michigan Comprehensive Cancer Center. Lynch syndrome is an inherited condition linked to a higher risk of several types of cancer... Read More
Patients Benefit From Personalized Therapy Following Development Of New Multiple Myeloma Treatment Guidelines
Apr 02, 2013
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy... Read More
Mutated Histone Directly Links A Protein To A Rare Brain Stem Cancer In Children
Apr 02, 2013
Most cancer treatments are blunt. In an attempt to eradicate tumors, oncologists often turn to radiation or chemotherapy, which can damage healthy tissue along with the cancerous growths. New research from C. David Allis' laboratory at Rockefeller University may bring scientists closer to designing cancer therapeutics that can target tumors with pinpoint accuracy... Read More
Targeting Early-Morning Smoking May Reduce Risk For Lung And Oral Cancers
Apr 02, 2013
The sooner a person smokes a cigarette upon waking in the morning, the more likely he or she is to acquire lung or oral cancer, according to Penn State researchers... Read More
The Effects Of Combined Hormone Therapy On Breast Cancer Risk
Apr 02, 2013
Dr. Rowan Chlebowski, MD, PhD, Los Angeles Biomedical Research Institute lead researcher and author of a study released by the Journal of the National Cancer Institute, issued the following statement regarding the latest findings from the Women's Health Initiative, the largest-ever study of hormonal therapy in post-menopausal women. The study Dr... Read More
Coal-Tar-Sealing Of Pavements May Increase Risk Of Cancer
Apr 02, 2013
People living near asphalt pavement sealed with coal tar have an elevated risk of cancer, according to a study in the journal Environmental Science and Technology. Much of this calculated excess risk results from exposures in children, age six or younger, to polycyclic aromatic hydrocarbons (PAHs) from the sealant... Read More
Potential New Treatments For Hormone-Therapy-Related Breast Cancers
Apr 02, 2013
More than 100 women per day die from breast cancer in the United States. The odds of developing breast cancer increase for women taking hormone replacement therapy to avoid the effects of menopause. New research by University of Missouri scientist Salman Hyder may lead to treatments for breast cancers associated with taking these synthetic hormones... Read More
Novartis Loses In Patent Court Ruling, India
Apr 01, 2013
India's Supreme Court turned down Novartis' patent bid for an updated version of Glivec (imatinib mesylate), its blockbusting leukemia medication, saying that the updated compound "did not satisfy the test of novelty or inventiveness" required by the country's legislation. The ruling means that generic drugmakers can continue manufacturing and selling copies of Glivec at low prices... Read More
Previous Page Next Page